Brief: Knight Therapeutics Announces Approval Of Halaven In Colombia
06/01/2022 14:32
Jan 6 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS INC. ANNOUNCES APPROVAL OF HALAVEN IN
COLOMBIA
* KNIGHT THERAPEUTICS INC - COLOMBIAN AFFILIATE, BIOTOSCANA
FARMA
S.A. HAS OBTAINED INVIMA APPROVAL FOR HALAVEN INJECTION
Source text for Eikon: ID:nGNX2Ltcxw
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil